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ABSTRACT: 
Biomarkers are required to track disease progression and measure the effectiveness of interventions for 
people with spinocerebellar ataxia type-6 (SCA6). Gait is a potential biomarker that is sensitive to SCA6 
which can be measured using wearable technology, reducing the need for expensive specialist facilities. 
However, algorithms used to calculate gait using data from wearables have not been validated in SCA6. 
This study sought to examine the validity of a single wearable for deriving 14 spatio-temporal gait 
characteristics in SCA6 and control cohorts. Participants performed eight intermittent walks along a 7m 
instrumented walkway at their preferred walking pace while also wearing a single accelerometer-based 
wearable on L5. Gait algorithms previously validated in neurological populations and controls were 
used to derive gait characteristics. We assessed the bias, agreement and sensitivity of gait characteristics 
derived using the instrumented walkway and the wearable. Mean gait characteristics showed good to 
excellent agreement for both groups, although gait variability and asymmetry showed poor agreement 
between the two systems. Agreement improved considerably in the SCA6 group when people who used 
walking sticks were excluded from the analysis, suggesting poorer agreement in people with more 
severe gait impairment. Despite poor agreement for some characteristics, gait measured using the 
wearable was generally more sensitive to group differences than the instrumented walkway. Our 
findings indicate mean gait characteristics can be accurately measured using an accelerometer-based 
wearable in people SCA6 with mild-to-moderately severe gait impairment yet further development of 
algorithms are required for people with more severe symptoms.  





1.  INTRODUCTION: 
Spinocerebellar ataxia Type 6 (SCA6) is an autosomal dominant neurological condition that leads to 
degeneration of the Purkinje cells in the cerebellum (Schöls et al., 2004), resulting in slowly progressive 
impairment of balance (Bunn et al., 2013), coordination and gait (Klockgether, 2008). The absence of 
an effective biomarker of disease progression and response to treatment in SCA6 is a major hindrance 
for clinical trials (Underwood and Rubinsztein, 2008). However, recent evidence suggests that 
quantitative gait analysis may be a potential biomarker (Rochester et al., 2014). 
Gait ataxia can severely affect quality of life in people with SCA6 and is a prominent feature of the 
disease due to the critical involvement of the cerebellum in spatial accuracy and temporal coordination. 
In addition to gait dysfunction, symptoms include stance instability and balance impairment (Bunn et 
al., 2013) all of which negatively impact patient mobility, self-care and the capacity to perform activities 
of daily living (Schmitz‐Hübsch et al., 2010). Studies have found that gait characteristics of patients 
with cerebellar ataxia are globally impaired and certain characteristics show sensitivity to disease 
progression (Ilg et al., 2007; Serrao et al., 2012; Rochester et al., 2014). Gait velocity and variability 
derived from protocols such as the timed 10m walk (Serrao et al., 2012; Matsushima et al., 2015) are 
the most frequently reported gait characteristics for spinocerebellar ataxias. However, gait is complex 
and a more comprehensive model of these discriminant spatio-temporal characteristics has been used 
in both laboratory and free-living conditions for a range of neurological disorders (Rochester et al., 
2014; Schniepp et al., 2012).  
Gait analysis is typically assessed using complex optoelectronics, force platforms or pressure sensor 
walkways (Muro-de-la-Herran et al., 2014). However these techniques are costly, require expert 
personnel and are limited to specialist facilities and controlled environments (Taborri et al., 2016). 
When considering the low prevalence of ataxia (Falcon et al., 2016) it is unlikely that the majority of 
SCA6 patients have access to these specialist gait facilities. Wearable technology in combination with 
published algorithms and open-source platforms (Ladha et al., 2016) may provide a more pragmatic 
approach to gait analysis and facilitate cost effective assessment in a range of environments not 
exclusive to specialist centres (Del Din et al., 2016c). Accelerometer-based wearables (wearables) can 
provide comprehensive, longitudinal, continuous and objective measures of gait with greater flexibility 
than their laboratory-restricted counterparts. 
Therefore, spatio-temporal data derived from wearables have the potential to provide a cost-effective 
and portable method to derive an objective biomarker for monitoring gait in SCA6. However, the 
validity of this assessment tool and its associated algorithms for use in SCA6 has yet to be established. 
The aim of this study was to establish the validity of using a single accelerometer-based wearable worn 





Twenty-two people known to have the SCA6 mutation were recruited to this study. Participants were 
excluded if they were unable to walk 25m (independently: with or without a walking stick), or had any 
comorbidity influencing hearing and mobility (other than SCA6) that may have affected their safety or 
performance during the testing sessions. Ataxia severity was assessed using the International 
Cooperative Ataxia Rating Scale (ICARS) (Trouillas et al., 1997). Balance confidence was evaluated 
using the Activities Balance Confidence scale (ABCs). A retrospective self-report history of falls over 
the 3 month period prior to testing was also recorded. Twenty-three controls (recruited by 
advertisement) were also enrolled. Institutional ethical approval and written informed consent were 
obtained. 
2.2 Protocol 
Participants were required to perform eight single task (no auditory cue) 13m intermittent walks (Figure 
1), turn around and walk at their preferred walking pace while wearing a single wearable (2.3.1) located 
on the fifth lumbar vertebra (L5). A 7m instrumented walkway (2.3.2) was placed in the middle of the 
13m walk (Figure 1.). 
<Figure 1> 
2.3 Equipment 
2.3.1 Accelerometer-based wearable  
Participants were asked to wear a low-cost tri-axial accelerometer-based wearable (Axivity AX3; 
Axivity, York, UK; Dimensions: 23.0mm x32.5mm x7.6mm, weight 9g) located on L5. The wearable 
was attached using double sided tape and Hypafix (BSN Medical Limited, Hull, UK) and was 
programmed to capture with a sampling frequency of 100Hz (16 bit resolution, range ±8g). Recorded 
signals were stored locally on the sensor’s internal memory (512MB) as a raw binary file and then 
downloaded upon the completion of each testing session.  
  2.3.2 Instrumented walkway 
An instrumented walkway (Platinum model GaitRite, software version 4.5, CIR systems, NJ, USA; 
dimensions: 7.0m x 0.6m) was used as the gold standard measure of gait in this study. The instrumented 
walkway had a spatial accuracy of 1.27 cm and temporal accuracy of one sample (240 Hz, ∼4.17 ms) 
and is considered a valid and reliable measurement tool (Menz et al., 2004; Webster et al., 2005; Bilney 
et al., 2003; Galna et al., 2013). 
2.4 Data Processing 
Gait characteristics were selected a priori according to a validated model of gait which contains 16 gait 
characteristics across five domains: pace, variability, rhythm, asymmetry and postural control (Lord et 
al., 2013a; Lord et al., 2013b). Recent work has validated 14 gait characteristics from this model using 
wearable accelerometers in older adults and people with Parkinson’s disease (Del Din et al., 2015). 
Specifically, the gait characteristics and their associated domains examined in this study include the 
mean and variability of step velocity, length, and step, swing and stance time; and the asymmetry of 
step length, and step, swing and stance time. Gait characteristics were derived from left and right steps 
which were calculated separately and reported as the mean characteristics of left and right steps, gait 
variability characteristics were reported as the square root of the mean variance of left and right steps 
(resulting in the combined standard deviation of left and right steps independent of gait asymmetry), 
and gait asymmetry characteristics were calculated as the absolute difference between left and right step 
means (Galna et al., 2015).   
2.4.1 Wearable 
Previous assessments of gait using accelerometer-based wearables derive relatively few gait outcomes 
(Shirai et al., 2015). Raw acceleration data for this study were analysed using a bespoke MATLAB® 
(Version 2015a) program which implemented previously validated algorithms (McCamley et al., 2012; 
Zijlstra and Hof, 2003) to quantify 14 spatio-temporal gait characteristics with a wearable on L5 
(Godfrey et al., 2015; Godfrey et al., 2014; Del Din et al., 2015). Briefly, the initial (IC) and final 
contact (FC) events within the gait cycle are identified and used to estimate temporal characteristics 
(e.g. step time). This information was further used along with an inverted pendulum model to determine 
the spatial characteristics (e.g. step length) of the gait cycle. Calculating the product of step time and 
step length allows for the estimation of step velocity (Godfrey et al., 2015). The first and last three steps 
of each intermittent walk were removed so the wearable data would be congruent with the instrumented 
walkway. 
2.4.2 Instrumented Walkway:  
Data for individual steps for each walk were extracted from the instrumented walkway database using 
Microsoft Access 2007 (Microsoft Corp., Redmond, WA, USA). The same 14 characteristics derived 
from the raw acceleration data were calculated using a previous methodology (Del Din et al., 2015). 
2.5 Statistical Analysis 
The validity of the pooled walks for the wearable and the instrumented walkway were assessed using 
IBM SPSS Statistics Version 22. Shapiro-Wilks tests suggested the use of non-parametric measures 
(p<0.05). Mann-U Whitney tests were used to identify differences in gait performance between controls 
and ataxia participants.  
Bland-Altman plots were examined for both controls and SCA6 to visually check for nonlinear or 
heteroscedastic distributions of error between the two systems (instrumented walkway vs wearable) as 
a function of the participants’ mean gait performance.  
The bias (difference of Walkway-Wearable) of the two measures was assessed using Wilcoxon 
matched-pairs tests. Spearman’s correlations and intra-class correlations (ICC(2,1)) were used to examine 
the relative and absolute agreement of 14 spatio-temporal characteristics derived from the wearable and 
walkway respectively.   
Preliminary examination of the Bland-Altman plots identified five consistent outliers in the SCA6 group 
(Figure 2). Further examination showed that these participants were the only five to use walking sticks. 
We explored this further by presenting the analyses including the whole SCA6 cohort and also when 




Analysis of the group differences showed that there were no statistically significant differences between 
controls and SCA6 participants for age, height, weight and BMI. However, people with SCA6 had less 
confidence in their balance. These results were also true for the two subgroups of ataxia i.e. those who 
walked with and without walking aids (Table 1). 
<Table 1> 
3.2 Gait Differences 
Comparison of the gait performance between the two groups showed that distinct differences exist 
between controls and SCA6 participants. Significant group differences in gait were seen for 9 of the 14 
characteristics when using data from the instrumented walkway, whereby people with SCA6 
demonstrated impaired pace (step velocity and step length, and swing time asymmetry), rhythm (step 
time and stance time) and variability (step length and velocity variability, and step and stance time 
variability). In contrast we found significant group differences for 12 of the 14 characteristics (all 
variables except step velocity variability and step length asymmetry) when using data obtained using 
the wearable. This could be associated to the wearable’s greater sensitivity for gait asymmetry in the 




Consistent with previous validations of the wearable and its associated gait algorithms (Del Din et al., 
2015; Godfrey et al., 2015), pace (step velocity and step length) and rhythm (step time and stance time) 
domains showed excellent relative and absolute agreement and little bias in comparison to the GaitRite 
system. However variability, asymmetry (swing and step time asymmetry) and postural control (step 
length asymmetry) characteristics showed poor relative and absolute agreement and were subject to bias 
(Table 3: Stage 1). In general the temporal algorithm demonstrated greater agreement with the reference 
measure for controls. 
3.3.2 All SCA6 participants 
SCA6 gait showed excellent relative and absolute agreement, and no presence of bias for rhythm 
characteristics (step and stance time). Pace (step velocity and step length) and variability (step length, 
step time and stance time variability) characteristics demonstrated good to excellent relative and 
absolute agreement but were subject to bias. Asymmetry (swing time, step time asymmetry) and 
postural control (step length asymmetry) domains performed poorly (Table 3: Stage 1). Similar to 
controls, the temporal algorithm appears to generate greater agreement than its spatial counterpart. 
3.3.3 SCA6 who did not use walking aids 
Removal of the SCA6 participants who used walking aids improved the performance of the gait 
algorithms in pace (step velocity and step length), rhythm (step time and stance time) and variability 
(stance time variability) domains. However poor agreement was still observed for asymmetry (swing, 
stance and step time asymmetry) and postural control (step length asymmetry) characteristics (Table 3: 
Stage 2). Removing the five outliers using walking aids improved the performance of both the validity 
of characteristics derived from both the temporal and spatial algorithms.  
<Table 3> 
4. DISCUSSION: 
In place of complex, laboratory-based gait analysis systems, and rudimentary outcomes derived from 
commercial sensors, wearables employing algorithms that derive spatio-temporal characteristics have 
been shown to be a valid method for assessing gait for a range of neurodegenerative disorders (Del Din 
et al., 2016b). This study is the first to examine the validity of a comprehensive battery of spatio-
temporal gait characteristics using a single wearable worn on the lower back and its associated 
algorithms for robust gait assessment in SCA6.   
Mean gait characteristics have demonstrated good to excellent agreement with the reference measure 
(instrumented walkway) for both controls and SCA6 participants. In general it appears that the 
algorithms underestimate mean characteristics for controls and overestimate mean characteristics for 
SCA6. Variability and asymmetry values are less consistent and should be treated with caution. 
Although we have reported poor agreement between the instrumented walkway and wearable, the 
wearable was more sensitive in identifying group differences than the instrumented walkway suggesting 
it can still provide useful information regarding physical function. 
In general, the algorithms performed consistently for controls and have resulted in absolute differences 
comparable to previous validations of the methodology (Del Din et al., 2015; Godfrey et al., 2015). 
However poorer agreement, specifically for spatial characteristics, was seen in people who used 
walking sticks.  It is unlikely that the poor agreement was due solely to the use of a walking stick, but 
rather that this subgroup of people presented with poorer physical dysfunction (ICARS Table 1), more 
impaired gait (Table 2) and atypical kinematics.  Therefore, the resultant acceleration patterns differ 
significantly from those on which the algorithms were originally designed. Namely, the acceleration 
signals generated by these slower and more affected participants using walking sticks may affect the 
peak to peak detection accuracy of the temporal algorithm and the quality of the vertical displacements 
required for the spatial algorithm. We recommend manipulations to the gait algorithms used in this 
study may provide more robust measures of gait that compensate for disease related dysfunction. 
Previous validations have suggested that wearables may provide more sensitive measures of variability 
and asymmetry characteristics for differentiating between controls and pathological groups (Del Din et 
al., 2015). For this study, the wearable was able to better distinguish between the two groups (12/14 vs 
9/14 significantly different characteristics: wearable vs instrumented walkway respectively), especially 
in the asymmetry domain. This increased sensitivity observed across the other gait domains for the 
wearable is encouraging.  
There are limitations of this study that should be considered. Although the SCA6 cohort can be 
considered small in comparison investigations of more prevalent movement disorders, the majority of 
studies examining cerebellar dysfunction utilise cohorts combining ataxic subtypes. This study presents 
data from a genetically defined homogenous population of SCA6 which prevents the convolution of 
autosomal dominant and recessive subtypes improving the strength our findings. The disparity between 
our testing measures i.e. the continuous signal analysis employed by the wearable and the intermittent 
footfall detection of the instrumented walkway, could be a potential source of error between the two 
systems as calculations of variability and asymmetry are fundamentally different between them. 
Additional validation using stereophotogrammetry may provide valuable insights into why gait 
characteristics measured using instrumented walkways differ to wearables-derived measures. In 
addition, the current algorithms do not allow for calculation of the postural control characteristics of 
step width and step width variability from a single wearable worn on the lower back (Godfrey et al., 
2015). This is of concern when measuring gait ataxia, as step width variability is sensitive to SCA6, 
even in the pre-clinical stages of the disease (Rochester et al., 2014). Therefore, we recommend the 
inclusion of algorithms to provide proxy markers of gait-related postural control. 
With current applications of wearables for gait analysis extending beyond the confines of laboratory 
based protocols, the use of these measures for free-living gait analysis has already been described for 
other neuropathological groups (Del Din et al., 2015; Del Din et al., 2016a; Del Din et al., 2016b). This 
ubiquitous monitoring protocol has the potential to provide a more information rich two-tiered model 
of gait, harmonising behavioural information from ‘macro’ gait characteristics (such as the volume and 
pattern of walking bouts) measured using long term monitoring in free-living environments with the 
spatio-temporal information or ‘micro’ analysis as described in this study. The benefits of using such 
wearable devices rather than traditional complex laboratory based motion capture systems are varied 
and include; the flexibility of assessment environment, the simplification of testing administration, and 
increased processing and computational efficiency. The combination of such measures, and their 
feasibility should continue to be explored as gait is further assessed as a biomarker for SCA6. 
5. CONCLUSION: 
Mean gait characteristics derived from a single accelerometer-based wearable worn on the lower back 
are valid for assessing people with mild-to-moderately severe SCA6 but not for people with more severe 
gait impairment. The continuous signal analysis of wearables provides more sensitive measures of gait 
asymmetry for differentiating SCA6 and controls in comparison to instrumented walkways. The utility 
of this more comprehensive list of gait characteristics should be further assessed in free-living 
conditions as research continues to develop sensitive biomarkers of disease progression and response 
to interventions for SCA6. 
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9. FIGURES AND TABLES 
Figure 1: A) Location of the wearable on the lower back for walking trials. B) Experimental protocol for the 8 
intermittent walks: A single trial constitutes a walk from the beginning of the 13m to the end, for example left-
to-right above. Intermittent trials are recorded by successively walking over and back the walkway with brief 
pauses for turning at either side. 
Table 1: Demographics 
  CONTROLS SCA6 SCA6 (no WA) SCA6 (with WA) 
 Demographics (n=23) (n=22) (n=17) (n=5) 
  Mean SD Mean SD Mean SD Mean SD 
Age (yrs) 51.30 12.31 57.18 12.85 55.24 13.45 63.80 8.53 
Sex 15F/8M - 15F/7M - 12F/5M - 3F/2M - 
Height (m) 1.67 0.10 1.67 0.09 1.66 0.09 1.68 0.08 
Weight (kg) 73.70 13.29 80.16 14.06 79.54 15.81 82.28 5.61 
BMI 26.52 4.37 28.84 4.00 28.78 4.51 29.05 1.51 
Disease duration - - 113.95 70.25 100.98 56.79 145.09 95.68 
ABCs 96.03* 3.64 61.92* 24.51 70.98* 18.79 34.75* 19.66 
ICARS - - 18.50 11.12 16.13 9.95 25.60 12.52 
Demographics for the control, SCA6, and SCA6 subgroups respectively (*Significant group difference, p<0.05). 
The SCA6 subgroups are defined by those with or without a walking aid (WA). 
 
 
Figure 2: Bland Altman plots for SCA6 participants (walking-stick group denoted by ‘X’) for step time mean 
(rhythm domain-representative of temporal algorithm) and step length mean (pace domain-representative of the 
spatial algorithm) characteristics. Figure A and B demonstrate the graphs with all participants included whereas 
C and D have excluded walking aid participants.  
Table 2: Group Differences 
Gait Model 
GAITRITE WEARABLE 
CONTROLS (n=23) ATAXIA (n=22) CONTROLS (n=23) ATAXIA (n=22) 
Median (25th,75th percentile) Median (25th,75th percentile) 
Pace 
Step Velocity Mean (m.s-1) 1.465 (1.319, 1.625) 1.015 (0.843, 1.339)** 1.481 (1.356, 1.582) 1.142 (0.972, 1.380)** 
Step Length Mean (m) 0.747 (0.689, 0.785) 0.575 (0.439, 0.739)** 0.748 (0.671, 0.795) 0.645 (0.573, 0.752)** 
Swing Time Variability (s) 0.010 (0.009, 0.013) 0.020 (0.017, 0.034)** 0.013 (0.010, 0.018) 0.031 (0.024, 0.053)** 
Rhythm 
Step Time Mean (s) 0.508 (0.472, 0.546) 0.560 (0.531, 0.584)** 0.506 (0.469, 0.547) 0.559 (0.532, 0.597)** 
Swing Time Mean (s) 0.387 (0.359, 0.400) 0.392 (0.373, 0.420) 0.357 (0.331, 0.395) 0.408 (0.381, 0.437)** 
Stance Time Mean (s) 0.630 (0.593, 0.689) 0.726 (0.665, 0.787)** 0.676 (0.620, 0.721) 0.732 (0.686, 0.767)** 
Variability 
Step Velocity Variability (m.s-1) 0.048 (0.040, 0.059) 0.070 (0.057, 0.075)** 0.087 (0.068, 0.108) 0.094 (0.085, 0.163) 
Step Length Variability (m) 0.016 (0.014, 0.021) 0.030 (0.021, 0.043)** 0.038 (0.031, 0.043) 0.051 (0.039, 0.077)** 
Step Time Variability (s) 0.012 (0.009, 0.015) 0.026 (0.017, 0.036)** 0.015 (0.012, 0.023) 0.038 (0.025, 0.056)** 
Stance Time Variability (s) 0.012 (0.010, 0.017) 0.035 (0.022, 0.043)** 0.016 (0.012, 0.021) 0.037 (0.025, 0.060)** 
Asymmetry 
Swing Time Asymmetry (s) 0.004 (0.003, 0.007) 0.007 (0.004, 0.015) 0.011 (0.009, 0.021) 0.032 (0.021, 0.037)** 
Step Time Asymmetry (s) 0.006 (0.002, 0.011) 0.010 (0.006, 0.016) 0.012 (0.008, 0.022) 0.029 (0.023, 0.042)** 
Stance Time Asymmetry (s) 0.005 (0.003, 0.007) 0.007 (0.002, 0.015) 0.011 (0.009, 0.021) 0.031 (0.021, 0.035)** 
Postural Control Step Length Asymmetry (m) 0.010 (0.002, 0.026) 0.024 (0.003, 0.042) 0.031 (0.019, 0.046) 0.037 (0.031, 0.059) 
Comparison of group gait performance derived from GaitRite using a previously validated model of gait as a framework, (**  Significant difference observed at p<0.01).
Table 3: Validation Results 























Step Velocity Mean (m.s-1) -0.0001 (-0.0561, 0.0845) .818** .916** -.213 
Step Length Mean (m) -0.0060 (-0.0290, 0.0367) .744** .893** -.365 
Swing Time Variability (s) 0.0027 (0.0000, 0.0060) .267 .312 -3.072** 
Rhythm 
Step Time Mean (s) -0.0002 (-0.0068, 0.0014) .985** .996** -1.186 
Swing Time Mean (s) -0.0271 (-0.0403, -0.0094) .765** .739** -3.680** 
Stance Time Mean (s) 0.0371 (0.0083, 0.0447) .903** .895** -4.136** 
Variability 
Step Velocity Variability (m.s-1) 0.0368 (0.0213, 0.0608) -.023 .032 -3.924** 
Step Length Variability (m) 0.0206 (0.0142, 0.0304) -.042 .009 -4.197** 
Step Time Variability (s) 0.0040 (-0.0016, 0.0128) .112 .082 -2.464* 
Stance Time Variability (s) 0.0040 (-0.0022, 0.0093) .143 .223 -2.220* 
Asymmetry 
Swing Time Asymmetry (s) 0.0068 (0.0003, 0.0168) -.003 .542** -3.711** 
Step Time Asymmetry (s) 0.0068 (0.0020, 0.0191) .084 .542** -3.437** 
Stance Time Asymmetry (s) 0.0075 (0.0037, 0.0148) .349 .536** -3.771** 












Step Velocity Mean (m.s-1) 0.1004 (0.0207, 0.1653) .947** .924** -2.776** 
Step Length Mean (m) 0.0676 (0.0056, 0.0873) .749** .768** -2.841** 
Swing Time Variability (s) 0.0101 (0.0035, 0.0273) .854** .911** -3.912** 
Rhythm 
Step Time Mean (s) 0.0002 (-0.0080, 0.0040) .946** .978** -.438 
Swing Time Mean (s) 0.0280 (-0.0094, 0.0684) .523* .669** -2.484* 
Stance Time Mean (s) -0.0109 (-0.0310, 0.0238) .859** .877** -0.763 
Variability 
Step Velocity Variability (m.s-1) 0.0371 (0.0180, 0.0932) .391 .259 -3.523** 
Step Length Variability (m) 0.0216 (0.0136, 0.0482) .723** .309 -4.010** 
Step Time Variability (s) 0.0140 (0.0026, 0.0233) .764** .911** -3.620** 
Stance Time Variability (s) 0.0064 (-0.0025, 0.0150) .858** .959** -2.094* 
Asymmetry 
Swing Time Asymmetry (s) 0.0201 (0.0118, 0.0289) .388 .687** -3.393** 
Step Time Asymmetry (s) 0.0193 (0.0096, 0.0254) .374 .428 -2.743** 
Stance Time Asymmetry (s) 0.0212 (0.0124, 0.0277) .596** .645* -3.393** 




























Step Velocity Mean (m.s-1) 0.0697 (-0.0171, 0.1319) .919** .952** -1.823 
Step Length Mean (m) 0.0365 (-0.0070, 0.0748) .907** .940** -1.775 
Swing Time Variability (s) 0.0072 (0.0020, 0.0151) .740** .590* -3.337** 
Rhythm 
Step Time Mean (s) -0.0001 (-0.0071, 0.0022) .995** .997** -.876 
Swing Time Mean (s) 0.0065 (-0.0131, 0.0406) .471 .679* -1.302 
Stance Time Mean (s) -0.0027 (-0.0261, 0.0242) .929** .917** -.308 
Variability 
Step Velocity Variability (m.s-1) 0.0309 (0.0159, 0.0449) .444 .418 -2.817** 
Step Length Variability (m) 0.0183 (0.0115, 0.0326) .591* .406* -3.479** 
Step Time Variability (s) 0.0084 (0.0009, 0.0191) .591* .698** -2.959** 
Stance Time Variability (s) 0.0042 (-0.0025, 0.0112) .775** .887** -1.870 
Asymmetry 
Swing Time Asymmetry (s) 0.0221 (0.0120, 0.0291) .238 .117 -3.621** 
Step Time Asymmetry (s) 0.0196 (0.0115, 0.0243) .244 .043 -3.574** 
Stance Time Asymmetry (s) 0.0220 (0.0130, 0.0268) .404 .231* -3.621** 
Postural Control Step Length Asymmetry (m) 0.0226 (0.0054, 0.0370) .466 .411* -3.243** 
 Relative (Spearman’s ‘RHO’) and absolute agreement (intraclass correlations ‘ICC’), and bias (Wilcoxon ‘Z’) 
results for A) Stage 1: Controls and SCA6 respectively and B) Stage 2: SCA6 with no walking aids (*Significant 
at p<0.05, **Significant at p<0.01). 
